Acute Regime for Severe Preeclampsia / Impending Eclampsia

Threshold for Acute Intervention

Step 1 — Seizure Prophylaxis: Magnesium Sulfate

• Antidote: Calcium gluconate 1 g IV slowly — reverses hypermagnesemia
• Stop infusion if reflexes lost or RR decreases / end-tidal CO₂ rises
• Maintain urine output >25 mL/hr (Mg is renally cleared)

Magnesium also acts as a mild vasodilator — increases prostacyclin release, decreases plasma renin and ACE activity — but is not primarily an antihypertensive. Continue it through labor and ≥24 hours postpartum.

Step 2 — Antihypertensive Therapy

First-Line Agents (ACOG-endorsed)

Second-Line Agents (if first-line fails — requires specialist consultation)

Step 3 — Persistent or Active Eclamptic Seizures

1. Lorazepam 2–4 mg IV; may repeat ×1 after 10–15 min
2. Phenytoin / Fosphenytoin 15–20 mg/kg IV; may repeat 10 mg/kg after 20 min
3. Levetiracetam 20–60 mg/kg IV; may repeat in 12 hours
4. Propofol or midazolam — small dose to terminate seizure lasting >5 minutes (avoid polypharmacy; preserve ability to perform neurological exam)

• Seizures recurrent or focal
• Seizures persist despite therapeutic Mg
• Decreasing consciousness beyond postictal period
• Lateralizing neurological signs

Step 4 — Immediate Supportive Measures

Step 5 — Laboratory Assessment (End-Organ Evaluation)

• CBC + platelets (thrombocytopenia → HELLP)
• LFTs (hepatocellular injury, HELLP)
• BUN, creatinine (renal dysfunction)
• LDH, peripheral smear (hemolysis)
• Coagulation panel if DIC suspected
• Urinalysis / spot protein:creatinine (baseline only; repeat not needed once diagnosis made)

Step 6 — HELLP Syndrome (Concurrent Management)

• IV magnesium + BP control + admission
• Correct coagulopathy if clinically indicated
• Corticosteroids if <34 weeks (improve fetal outcome, may delay delivery)
• Definitive treatment: delivery, especially at ≥34 weeks

Step 7 — Delivery (Definitive Treatment)

• Eclampsia = indication for delivery, not necessarily cesarean
• Assess whether induction is feasible vs. urgent cesarean
• Neuraxial analgesia is preferred for labor in severe preeclampsia/eclampsia — attenuates hypertensive response to pain, reduces catecholamines
  • Check platelet count before placement (thrombocytopenia risk)
• Monitor fetus continuously — fetal HR abnormalities during seizure usually resolve post-ictally; do not rush to emergency CS unless abruption or cord prolapse

Invasive Monitoring — When to Consider

Quick Reference Summary

BP ≥160/110 for ≥15 min  →  ACTIVATE PROTOCOL

1. MgSO₄ 4–6g IV over 15–20 min  →  2g/hr maintenance
2. Antihypertensive: Labetalol 20mg IV  OR  Hydralazine 5mg IV  OR  Nifedipine 10mg PO
3. O₂, lateral positioning, suction, Foley, restrict fluids
4. Labs: CBC, LFT, BUN/Cr, coags
5. Fetal monitoring
6. Plan delivery — OB consult urgently

• Rosen's Emergency Medicine, Box 173.4
• Tintinalli's Emergency Medicine, Table 100-4
• Creasy & Resnik's Maternal-Fetal Medicine, Preeclampsia with Severe Features section

Treatment Approach for Urge Urinary Incontinence (UUI) / Overactive Bladder (OAB)

Step 1 — First-Line: Behavioral & Conservative Therapy

Bladder Training

• Gradually increase voiding intervals by resisting the urge to void
• Start voiding every 1–1.5 hours and extend by 15–30 min increments weekly until reaching 3–4 hour intervals
• Effective evidence base for urgency incontinence specifically

Pelvic Floor Muscle Training (PFMT / Kegel exercises)

• Strengthens the external urethral sphincter and pelvic floor to inhibit detrusor contractions
• Effective for stress, urge, and mixed incontinence
• Ideally guided by a pelvic floor physiotherapist

Biofeedback

• Augments PFMT by providing real-time feedback on muscle activity
• Useful when patients cannot identify the correct muscles

Fluid & Dietary Modification

• Reduce total daily fluid intake if excessive (aim ~1.5–2 L/day)
• Eliminate or reduce bladder irritants: caffeine, alcohol, carbonated drinks, artificial sweeteners, spicy/acidic foods
• Recent systematic review (PMID 40105788) confirms a significant association between specific dietary irritants and OAB symptom severity

Urgency Suppression Techniques

• "Freeze and squeeze" — contract pelvic floor muscles when urgency arises, then walk calmly to the toilet

Electrical Stimulation

• Transcutaneous or intravaginal electrical stimulation inhibits detrusor overactivity

Step 2 — Second-Line: Pharmacotherapy

A. Antimuscarinics (Anticholinergics) — Primary Drug Class

• Dry mouth (most common — salivary glands)
• Constipation (GI)
• Blurred vision (ciliary muscle)
• Tachycardia (heart)
• Cognitive impairment / memory problems (CNS — especially in elderly)

• Start at the lowest dose; uptitrate after 4–6 weeks if insufficient response
• Extended-release formulations are better tolerated than immediate-release (fewer side effects, once-daily dosing)
• If side effects occur, switch to a different anticholinergic before abandoning the class
• Trospium is the preferred choice in cognitively impaired patients — it is hydrophilic with large molecular size, limiting CNS penetration
• Avoid anticholinergics in patients with: narrow-angle glaucoma, urinary retention, severe constipation, myasthenia gravis
• ⚠️ Dementia concern: Growing evidence links chronic anticholinergic use to increased dementia risk in elderly patients — prefer mirabegron in this population

B. Beta-3 Adrenergic Agonist — Mirabegron

• Dose: 25–50 mg once daily
• FDA approved: 2012
• Advantages: No dry mouth, constipation, or blurred vision; safe in cognitive impairment
• Cautions: Use with care in uncontrolled hypertension (raises BP), renal or hepatic impairment, urinary retention
• Efficacy: Comparable to antimuscarinics; better tolerability in head-to-head trials vs. tolterodine
• Combination therapy: Mirabegron + antimuscarinic (e.g., solifenacin) shows additive symptom control — supported by accumulating evidence

C. Topical Vaginal Estrogen (women)

• Reduces urogenital atrophy contributing to OAB symptoms in postmenopausal women
• Short-term use recommended; avoid oral estrogen (worsens incontinence, cardiovascular and cancer risks)

D. Tricyclic Antidepressants (Imipramine)

• Anticholinergic + central sedative action; increases bladder capacity
• Limited RCT data; used when other agents fail or for concurrent nocturia/enuresis

Step 3 — Third-Line: Advanced / Interventional Therapies

1. Posterior Tibial Nerve Stimulation (PTNS)

• Acupuncture-type needle inserted near the ankle, stimulates the tibial nerve (S3 reflex arc)
• 30-minute sessions, weekly × 12 weeks
• Proven superior to sham therapy with reasonably sustained long-term effect
• Minimally invasive, office-based procedure

2. Sacral Neuromodulation (SNS / InterStim)

• Implantable device stimulates S3 sacral nerve roots
• Activates afferent inhibitory pathways and cortical areas controlling bladder function
• FDA approved for urgency-frequency with or without incontinence
• ~2/3 of refractory OAB patients respond
• Effective even in severe and complex cases; also indicated for non-obstructive urinary retention

3. Intradetrusor Botulinum Toxin A (OnabotulinumtoxinA / Botox)

• Injected into the detrusor muscle via cystoscope (local anesthesia or light sedation)
• Blocks acetylcholine release → detrusor relaxation
• Effects last 3–6 months; repeat injections when symptoms recur
• Efficacy comparable to sacral neuromodulation
• Risk: urinary retention (patients must be counseled on and willing to perform self-catheterization if needed)

4. Bladder Augmentation / Urinary Diversion

• Reserved for neurogenic bladder with severe refractory spasticity
• Rarely needed in idiopathic OAB

Step-Up Summary

First-Line (start here)
│
├── Bladder training + urgency suppression techniques
├── PFMT / pelvic floor physiotherapy ± biofeedback
└── Dietary modification (reduce caffeine, alcohol, irritants)
          │
          ▼ (if insufficient after 4–8 weeks)
Second-Line
│
├── Antimuscarinic (e.g., tolterodine LA 4 mg OD, solifenacin 5 mg OD)
│     OR
└── Mirabegron 25–50 mg OD (preferred in elderly/cognitively impaired)
│   Consider combination (antimuscarinic + mirabegron) for added effect
          │
          ▼ (refractory — failed ≥2 medications)
Third-Line
│
├── PTNS (office-based, non-invasive)
├── Sacral neuromodulation (implant)
└── Intradetrusor Botulinum Toxin A (cystoscopic injection)

• Elderly / dementia risk: Prefer mirabegron over antimuscarinics; trospium if antimuscarinic required
• Men with concurrent BPO: Evaluate for bladder outlet obstruction first; alpha-blockers may help both LUTS and OAB
• Neurogenic OAB (MS, spinal cord injury): Antimuscarinics + CIC; SNS; BTX-A; augmentation if needed
• Postmenopausal women: Add topical vaginal estrogen if atrophic vaginitis present

• Smith & Tanagho's General Urology, 19th Ed.
• Berek & Novak's Gynecology, Table 29-9
• Textbook of Family Medicine, 9th Ed., Table 40-15
• Campbell-Walsh-Wein Urology (Incontinence Treatment Overview)